Back in January, The World Health Organization (WHO) declared Covid-19 a global public health emergency. Due to several reasons countries, the decision came about. Firstly, the coronavirus has the potential to kill. Those who suffer from chronic health conditions and underlying health problems are the most vulnerable.
The virus is also extremely contagious and at the same time, there’s is very little we know about it. We only know about the virus for a few months so it is quite new.
Because the virus is so recent the existing public health tools used to contain it don’t work very well; often not those tools and measures fail to be implemented in the right way or effectively enough. Because of this, the effects of the virus on the economy and society can be severe. Health officials;’s measures use tactics in the line of quarantines and social distancing; meanwhile, hospitals use oxygen and fever reducers, such as ibuprofen, in the treatments. The fact that so many people get the disease in so short time creates fear equipment shortages and also puts a restrain on healthcare systems.
As a result scientists race to test an experimental coronavirus vaccine. This means that researchers are rushing to try it on people. However, they don’t know how well it prevents infection in animals. With most countries going quarantined flights being banned; also events being canceled creates enormous pressure to find a solution to the problem.
China will test the coronavirus vaccine next April.
Next month some of the drugs currently on development will enter the clinical research phase.
Chinese doctors could have the first vaccines against the new coronavirus for emergencies starting in April. This is information dated March 6; from Zheng Zhongwei, the director of the Center for Development of Science and Technology of the National Health Commission.
The senior Chinese official said that Beijing expects some of the vaccines ‘to enter the clinical research phase. If not in this case in particular, they might also be useful in emergencies next month, according to the South China Morning Post.
Chinese law indicates that vaccines developed for public health emergencies can be used, in dire need, under specific conditions. But only if the National Administration of Medical Products believes that the benefits outweigh the risks.
The agency approved the use of a rapid test kit to detect SARS-CoV-2 that offers results in 29 minutes. this kit also passed clinical trials in Wuhan hospitals.
-Chinese health authorities reported that almost 70% of people affected by the new coronavirus recovered and are at home.
Trump is trying to get a German pharmaceutical company to develop the coronavirus vaccine just for the US.
Berlin negotiates with the company CureVac so that it does not transfer its research and insists that no country should have a monopoly on any future vaccine The government of Germany is trying to prevent Washington persuade a German company looking for a vaccine against the coronavirus to move their research to the United States.
This situation created polemics worldwide. German politicians maintain the opinion that the complete control of any future vaccine shouldn’t belong to any country This is a monopolistic practice and they do not agree with it.
Routers received information from German government sources on the topic. The information stated that the United States administration was looking into how they might obtain access to a possible vaccine against the coronavirus; said research is under CureVac company of German origin.
The company has its base in Tübingen and also it is a private business. They expect to have an experimental vaccine in the next three months (by June or July)
This Sunday, the German newspaper Welt am Sonntag issued a report. It said that the President of the United States, Donald Trump, offered funds to attract CureVac to the United States. As a consequence, the German government made counter-offers, in turn, tempt them to stay.
The company rejects current rumors of an acquisition.
A statement from CureVac rejects current acquisition rumors. They confirmed that the firm had contact with several authorities and organizations all over the world but rejected ‘allegations of offers to acquire the company or its technology.‘
The company is working with various candidates to eventually select the best to be part of the clinical trials. They hope to have an experimental vaccine by June or July. The next step then would be to seek regulatory approval for human testing after that.
CureVac management said that early this month they met with the president of the United States, the vice president, members of the White House coronavirus task force, and senior representatives from pharmaceutical and biotech companies to discuss the creation of a vaccine.
Some of the most promising vaccines against coronavirus.
The world is in turmoil due to this virus and the speed at which it infects people. It has already killed nearly 10000 people worldwide. The response to science has been extraordinary and there are a number of vaccines on the horizon that could cure the disease. The Coalition for Epidemic Preparedness Innovations (CEPI) is a global alliance financing and coordinating the development of vaccines against emerging infectious diseases. Created after the Ebola pandemic in 2017, they are providing funds for many of the COVID vaccines.
1-The name of the vaccine is INO-4800. This Covid-19 vaccine candidate is the strongest one according to many. The company developing it is Pharmaceuticals. They already have a competent and CEPI-supported vaccine for MERS. MERS is a type of coronavirus that’s closely related to Covid-19. At the moment INO-4800 is currently in the preclinical phase and soon will be going through human trials.
2-mRNA-1273 is another vaccine. Funded by CEPI the vaccine comes from the NIAID and Moderna biotech. The name of this vaccine stands for “messenger ribonucleic acid.” Those molecules have the function to instruct cells to create certain proteins.
3-The biotech CureVac runs in third place. Their vaccine is similar to the one developed by NIAID and Moderna.